LODGE PARTNERS EST. 1994 · MELBOURNE · SYDNEY

Institutional research

Research

Independent, institutional-grade research on ASX-listed small and mid-cap companies from the Lodge Partners research desk.

Wholesale clients only Lodge Partners Pty Ltd (ABN 25 053 432 769) holds an Australian Financial Services Licence authorising dealings with wholesale clients only (AFSL 246271). Research published here is general securities advice made available solely to wholesale clients as defined in sections 761G and 761GA of the Corporations Act 2001 (Cth). It is not directed at, and must not be relied upon by, retail investors.
← Back to Lodge Partners
Filter
10 Jul 2026
Research update
Paradigm Bio Limited ASX: PAR
PARA_OA_012 — 100% dosed, interim in September
Price $0.17 · Valuation $1.74
Healthcare
BUY
15 Jun 2026
Research report
Haranga Resources ASX: HAR
402,000 ounces @ 5.1g/t and upside
Price $0.115 · Valuation $0.36
Resources — Gold
SPEC BUY
26 Mar 2026
Research report
Lakes Blue Energy ASX: LKO
Continuing to await flow rates at Wombat
Price $0.76 · Valuation $3.15
Energy — Oil & Gas
SPEC BUY
16 Feb 2026
Research update
Mesoblast Limited ASX: MSB
Survival rate in adults heightens potential
Price $2.38 · Valuation $4.71
Healthcare
BUY
28 Jan 2026
Research update
BlinkLab Ltd ASX: BB1
Pilot study confirms path to commerciality
Price $0.92 · Valuation $1.90
Healthcare
SPEC BUY

Disclaimer. Research published on this page is prepared by Lodge Partners Pty Ltd (ABN 25 053 432 769, AFSL 246271) and is made available to wholesale clients only. In accordance with section 949A of the Corporations Act 2001, it constitutes general advice in respect of a financial product and not personal advice: it has been prepared without taking account of any recipient's objectives, financial situation or needs, and recipients should consider its appropriateness to their own circumstances before acting on it. Ratings used are BUY (anticipated return greater than 10%), HOLD (between −10% and +10%), SELL (less than −10%) and SPECULATIVE BUY (high-risk stock, price likely to fluctuate by 50% or more, anticipated return greater than 10%). Companies covered are, or in the past 12 months were, clients of Lodge Partners' affiliated company and authorised representative Lodge Corporate Pty Ltd, which has received or expects to receive compensation for investment banking or corporate services from them — see the transaction archive. Lodge directors, consultants and advisers may hold interests in the securities referred to and Lodge earns broking commissions acting for clients trading those securities. Past performance is not a reliable indicator of future performance. Full disclosures are set out in each report.

Research access

Request research access.

Full research distribution is available to wholesale and institutional clients of the firm.